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maintained their injection practices 
for 8–10 years.1 Hence, evidence from 
field investigations supports our 
assumptions about frequent injectors. 
We did not validate our assumptions 
for  the general  population. 
Conceivably, individuals change 
their frequencies of undergoing 
medical procedures on the basis of 
age. However, these changes are 
not likely to substantially aﬀ ect the 
frequency of HCV transmission, unless 
individuals are frequent injectors. 
In conclusion, exclusion of age 
structure is not a major limitation of 
our modelling work. Interventions 
that target the top 2–5% of frequent 
injectors seems like a feasible 
approach, would be much more 
effective at reducing R0 than would 
untargeted interventions, and would 
not depend on substantial increases 
in logistical and financial resources 
beyond those already deployed for the 
existing national strategy.
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variables, R0 decreased substantially 
as well. However, HCV continued to 
be transmitted, to a lesser extent, 
through everyday medical procedures.3 
Hepatitis C has a very long chronic 
period, resulting in a very slowly 
evolving epidemic. A steady reduction 
in HCV prevalence in Egypt suggests 
that transmission in the era since 
mass parenteral anti-schistosomal 
therapy is insuﬃ  cient to maintain the 
HCV prevalence reached in the late 
1980s. However, a falling prevalence 
does not imply that HCV transmission 
variables and, implicitly, R0, saw further 
substantial decreases since the end of 
the mass campaigns. The only notable 
subsequent event, leading to further 
decrease in the R0 of the HCV epidemic 
in Egypt, might be the initiation of the 
present national strategy against the 
disease.
We did not identify age as a 
major factor shaping continuing 
HCV transmission and future 
seroprevalence. With every blood-
borne disease, these epidemiological 
variables depend on how frequently 
individuals  undergo medical 
procedures and the risk of acquiring 
HCV in each case. In our study,1 we 
used data to estimate the frequencies 
of undergoing medical procedures 
and assumed that these frequencies 
did not change substantially in 
the short term; we challenged 
this assumption in a field study of 
frequent injectors in a rural cohort. 
Advanced age was not a feature of 
frequent injectors; median age was 
32 years (IQR 15–45) at baseline. A 
follow-up study showed that they 
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We agree with James Jansson and 
David Wilson that universal treatment 
for hepatitis C virus (HCV) infection 
in Egypt is an ambitious public health 
strategy. This fact has been part of 
the motivation for our work. In our 
study,1 we identiﬁ ed that most HCV 
transmission in Egypt is caused by a 
core group of individuals undergoing 
frequent medical injections. The 
existing national treatment strategy 
does not target these individuals, 
who are thus treated in the same 
proportions as the general population, 
leading to only a small reduction in the 
basic reproduction number (R0; from 
3·54 to 3·03).1 However, individuals in 
this core group could be easily targeted 
with testing, prevention counselling, 
and treatment, as they identify 
themselves by accessing health care. 
Such targeted interventions could lead 
to a substantial reduction in R0 and, 
most importantly, HCV incidence.
The origins of the HCV epidemic 
in Egypt are attributed to mass 
campaigns of parenteral anti-
schistosomal therapy between 
the 1960s and the 1980s.2 Once 
these mass campaigns stopped, 
HCV transmission variables (key 
variables included in our model were 
frequency of medical injections, 
probability of reuse of injecting 
material, and infection probability 
by injection) decreased substantially. 
It is reasonable to assume that, 
since R0 depends strongly on these 
